222 related articles for article (PubMed ID: 26758564)
1. CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma.
Cuccaro A; Annunziata S; Cupelli E; Martini M; Calcagni ML; Rufini V; Giachelia M; Bartolomei F; Galli E; D'Alò F; Voso MT; Leone G; Giordano A; Larocca LM; Hohaus S
Cancer Med; 2016 Mar; 5(3):398-406. PubMed ID: 26758564
[TBL] [Abstract][Full Text] [Related]
2. Combined prognostic role of TARC and interim
Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z
Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858
[TBL] [Abstract][Full Text] [Related]
3. Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.
Viviani S; Mazzocchi A; Pavoni C; Taverna F; Rossi A; Patti C; Romano A; Trentin L; Sorasio R; Guidetti A; Gottardi D; Tarella C; Cimminiello M; Zanotti R; Farina L; Ferreri AJM; Galbiati M; Corradini P; Gianni AM; Gallamini A; Rambaldi A
Hematol Oncol; 2020 Oct; 38(4):501-508. PubMed ID: 32602970
[TBL] [Abstract][Full Text] [Related]
4. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
[TBL] [Abstract][Full Text] [Related]
5. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
6. Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma.
Guidetti A; Mazzocchi A; Miceli R; Paterno' E; Taverna F; Spina F; Crippa F; Farina L; Corradini P; Gianni AM; Viviani S
Leuk Res; 2017 Nov; 62():91-97. PubMed ID: 28992524
[TBL] [Abstract][Full Text] [Related]
7. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.
Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F
Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339
[TBL] [Abstract][Full Text] [Related]
8. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment.
Cencini E; Fabbri A; Rigacci L; Lazzi S; Gini G; Cox MC; Mancuso S; Abruzzese E; Kovalchuk S; Goteri G; Di Napoli A; Bono R; Fratoni S; Di Lollo S; Bosi A; Leoncini L; Bocchia M
Hematol Oncol; 2017 Mar; 35(1):69-78. PubMed ID: 26251194
[TBL] [Abstract][Full Text] [Related]
10. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
11. CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment.
Touati M; Delage-Corre M; Monteil J; Abraham J; Moreau S; Remenieras L; Gourin MP; Dmytruk N; Olivrie A; Turlure P; Girault S; Labrousse F; Preux PM; Jaccard A; Bordessoule D
Leuk Lymphoma; 2015 Feb; 56(2):332-41. PubMed ID: 24766492
[TBL] [Abstract][Full Text] [Related]
12. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.
Hsi ED; Li H; Nixon AB; Schöder H; Bartlett NL; LeBlanc M; Smith S; Kahl BS; Leonard JP; Evens AM; Scott DW; Rimsza LM; Friedberg JW
Blood; 2019 Apr; 133(16):1762-1765. PubMed ID: 30723079
[TBL] [Abstract][Full Text] [Related]
14. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.
Cerci JJ; Pracchia LF; Linardi CC; Pitella FA; Delbeke D; Izaki M; Trindade E; Soares J; Buccheri V; Meneghetti JC
J Nucl Med; 2010 Sep; 51(9):1337-43. PubMed ID: 20720036
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.
Le Roux PY; Gastinne T; Le Gouill S; Nowak E; Bodet-Milin C; Querellou S; Mahe B; Dubruille V; Blin N; Salaun PY; Bodere-Kraeber F
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1064-71. PubMed ID: 21308370
[TBL] [Abstract][Full Text] [Related]
17. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E
Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369
[TBL] [Abstract][Full Text] [Related]
18. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
19. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
20. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial.
Pavlovsky A; Fernandez I; Kurgansky N; Prates V; Zoppegno L; Negri P; Milone G; Cerutti I; Zabaljauregui S; Mariano R; Grecco HF; Basquiera AL; Saba S; Rudoy S; Sackmann F; Castano V; Remaggi G; Cabrejo M; Roveri E; Casale MF; Cabane V; Taus R; Venturini C; Sakamoto F; Varela AI; Riddick M; Pavlovsky S;
Br J Haematol; 2019 Jun; 185(5):865-873. PubMed ID: 30864146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
